Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

OrthoEvidence Chooses MEI Global to Spearhead Licensing Partnerships


MEIG’s expertise in identifying, negotiating, and managing deals with licensing partners in order to expand the reach of OrthoEvidence’s content means more patients, medical professionals, pharmaceutical companies and others will find the critical information they need, more easily.

Today OrthoEvidence Inc., an orthopedic-focused evidence-based summary provider, announced that it has chosen MEI Global LLC (MEIG), a leader in helping publishers monetize their digital assets, to create third party licensing partnerships to extend its content’s reach to a larger audience.

“Our goal is to provide critical information access to orthopedic healthcare providers and their patients everywhere,” says Dr. Mohit Bhandari, founder and president of OrthoEvidence. “To save medical professionals time and expand access to high quality research, we have developed a process to identify, critically appraise, and summarize the best of the best in the field of orthopedics.” He adds, “MEIG’s expertise in identifying, negotiating, and managing deals with licensing partners in order to expand the reach of OrthoEvidence’s content means more patients, medical professionals, pharmaceutical companies and others will find the critical information they need, more easily.”

MEIG was founded by Randall Marcinko to address the difficulty publishers experience developing new licensing opportunities, which is frequently due to a shortage of in-house licensing personnel.

“The market for content and the associated business models evolve rapidly. In a world of declining budgets, publishers are all too often forced to focus on publishing operations at the expense of a strategic focus on distribution,” says Marcinko. “Without the time and resources to focus on licensing or an in-depth understanding of the significant upside it can generate, publishers miss out on lucrative new markets. Having applied our proven analytical approach to OrthoEvidence’s content, our team is excited about the licensing opportunities to reach end users of all types via partnerships with aggregators, syndicators and others in the information industry.”

“We’re pleased that OrthoEvidence recognizes MEIG’s ability to quickly and strategically expand their content distribution partnerships,” says Chris Broekhoff, MEIG’s President. He says, “MEIG’s team will bring its acumen, professionalism, and a commitment to safeguarding publishers’ intellectual property to the long-term, profitable relationship we look forward to building with OrthoEvidence.”

About MEI Global LLC: MEIG provides a suite of services to help publishers monetize their digital assets. MEIG’s expertise includes prospecting, negotiating, relationship management, and extensive knowledge of vendors and their needs, thanks to decades of industry experience within MEIG’s dealmaker team. The company assists publishers with strategic decision making through a lens of revenue growth, brand extension and intellectual property protection. For additional information, please contact Vice President of Business Development Nancy Davis Kho at ndkho@marcinko.com, +1 510 336 1119.

About OrthoEvidence, Inc.: OrthoEvidence (OE) is a fast-growing online platform of innovative products and services targeted to evidence-based surgical practice, focusing on orthopedics. OE focuses on helping associations and industry architect, analyze, and educate their networks about health care decisions. OE’s competitive advantage derives from skilled data scientists, programmers, and analytics teams. Through automation and algorithms using machine learning, OE is building the business intelligence platform “OE M.I.N.D.- Machine learning INsights Database” with over 75 million datapoints to drive new analytics and evidence reports. For additional information, please contact Vice President, Sonia Dosanjh at sonia.dosanjh@myorthoevidence.com, +1 289 337 5717.

Share article on social media or email:

Hazel Health Adds COVID-19 Tools to Support Schools as They Navigate Public Health Crisis


News Image

“Hazel Health was founded upon the belief that all children deserve access to quality healthcare in order to excel – a mission that has become even more crucial with the COVID-19 pandemic,” said Josh Golomb, CEO at Hazel Health.

Hazel Health, the national leader in school-based healthcare, announces the release of essential COVID-19 tools that enable school district officials to reopen schools as safely as possible and meet local health regulations. The availability of the new tools comes at a time when more schools are reopening and COVID-19 cases are surging in the U.S.

Hazel Health’s COVID-19 safety tools include:


  • COVID-19 Screener: To support district health protocols, the COVID-19 screener enables parents to check and confirm symptoms their child may be experiencing before the child enters a school environment. On-demand visits are also available through the screener to address parents’ questions and concerns. Hazel Health designed the screener with ease of access and multilingual communities in mind.
  • Exposure Alert: As schools are notified of COVID-19 cases, Hazel Health’s Exposure Alert helps identify all students and staff exposed to each confirmed case and provides support and next steps for students. Notifications of positive cases are delivered instantaneously to district officials, enabling rapid response at the school and district level. Exposure Alert syncs with class schedule data from Clever to provide actionable information for campus safety.

“Hazel Health was founded upon the belief that all children deserve access to quality healthcare in order to excel – a mission that has become even more crucial with the COVID-19 pandemic,” said Josh Golomb, CEO at Hazel Health. “Inspiration for our new COVID-19 safety tools came directly from the education leaders we work with every day. Our goal is to support a safe and healthy learning environment and ensure healthcare for all students, in all communities, regardless of financial or immigration status.”

Through a secure, web-based platform, school nurses or parents at home can access Hazel Health from any device to coordinate care for students and request telehealth appointments with Hazel’s HIPAA and FERPA trained, board-certified healthcare providers.

“As we navigate the fluctuation of in-person and online learning, we’re thrilled to partner with Hazel Health and leverage their COVID-19 safety tools so we can provide a safe learning environment for students,” said Bridget Phillips, Chief Academic and Operations Officer, The Doral Academy of Nevada, a part of the Academia network of charter schools. “We were previously using Google Sheets to track symptoms, and had to manually comb through information – with Hazel Health’s system, there is proactive reporting which saves time and enables students to receive telehealth care sooner if there’s a potential positive.”

Hazel Health’s COVID-19 safety tools are HIPAA and FERPA compliant, with sensitive health data remaining within the secure platform. To learn more, please visit https://get.hazel.co/covid19.

About Hazel Health

Hazel Health is committed to eliminating barriers to quality healthcare for children. As the national leader in delivering pediatric telehealth care, Hazel Health partners with school districts across the U.S. and currently serves over 1.3M children. Hazel’s team of experienced pediatricians, educators, and best-in-class engineers are passionate about ensuring all children receive the best care in school or at home. Hazel is based in San Francisco, California. For more information, please visit http://www.hazel.co

Share article on social media or email:

Medify Air Launches Car Air Purifier with Professional Grade Filters


Designed to meet the rigorous standards of the World Health Organization, this in-vehicle air purifier adds another level of security for families and ride-share drivers while on the road.

Medify Air, the leading brand in providing solutions to improve indoor air quality, today announced the MA-CAR air purifier, designed to comfortably attach to the back of any vehicle’s headrest and provide clean, purified air. With air quality top of mind for most consumers during the COVID-19 pandemic, MA-CAR features HEPA H13 filters and a high clean air delivery rate (CADR) to effectively cycle all the air in a sedan or SUV every 10-15 minutes.

“The MA-CAR brings the clean, quality air standards provided in homes and businesses by our other air purifiers right to your car,” said J Henry Scott, CEO of Medify Air. “Designed to meet the rigorous standards of the World Health Organization, this in-vehicle air purifier adds another level of security for families and ride-share drivers while on the road.”

A lightweight, compact device, the MA-CAR is the ideal on-the-road air purifying solution for families, ride-shares and taxis, effectively removing up to 99.9% of airborne particles down to 0.1 microns. Additional features include:

  • Ability to Improve air quality for cars with seven seats or less, or up to 40 sq. ft.
  • Touch controls and three fan speeds
  • Velcro strap to conveniently secure the air purifier to any headrest

The MA-CAR is available for $99 on Amazon.com and MedifyAir.com. For more information on Medify Air’s complete portfolio of professional grade air purifiers, visit http://www.MedifyAir.com.

About Medify Air

Medify Air is the leading brand in providing improved and efficient air quality to help relieve the crisis of indoor air pollution. Our mission is to provide better and cleaner air for our customers to help them live longer and healthier lives. We do so by developing professional grade air purifiers utilizing highest-quality HEPA H13 filters in every model. We believe that the filter makes all the difference in producing healthier air for our customers. For more information, visit MedifyAir.com.

Press Contact

Cori Hays

medifyair@matternow.com

Share article on social media or email:

2020 Pediatric Perceptions & Insights Study Yields Important Insights on How to Enhance Pediatric Clinical Trial Participation


“Understanding patient health journeys and study volunteer experiences is critical to designing more patient-friendly trials that ultimately enhance pediatric patient participation,” said Ken Getz, Founder and Chairman at CISCRP.

A 2020 survey of 500 parents and children in the U.S. conducted by the Center for Information and Study on Clinical Research Participation (CISCRP) and commissioned by Parexel has yielded critical insights into why families choose to participate in clinical research and how to design clinical trials to better fit their needs, according to the survey report.

Pediatric participation in clinical trials is essential to understanding how drugs perform in children, whose physiologic responses to medications and unique disease variants are often different from adults.

While survey respondents expressed largely positive views of pediatric clinical research, actual participation in pediatric research remains low. Only 16.7 percent of clinical trials registered on the World Health Organization’s (WHO) portal involve pediatric patients, and only 12% of trials registered on clinicaltrials.gov are pediatric trials, even though children contributed to almost 60 percent of the total disease burden of the conditions being studied.1 As a result of low pediatric participation, the majority of drugs prescribed to children are only evaluated in adults.2

“Understanding patient health journeys and study volunteer experiences is critical to designing more patient-friendly trials that ultimately enhance pediatric patient participation, so that we can continue to develop newer, safer and more effective drugs for children,” said Ken Getz, Founder and Chairman at CISCRP.

Among the key findings from the survey:


  • Determinants: Parents cited their pediatrician’s recommendation as the most important factor when deciding to enroll their child in a trial, and they ranked the potential risks and benefits of the study drug as the most important information they needed to make a decision
  • Motivations: Children cited the desire to help scientists and doctors learn more about their disease as a primary motivation for participating
  • Barriers: 52 percent of children indicated it was very important to have some or all of their study visits at home if they were part of a research study
  • Diversity: Parents who identified as Black self-reported a better understanding of clinical research and were more willing to enroll their child in a clinical trial than parents who identified as Caucasian
  • Perceptions: The majority of children reported a positive experience with clinical trials, and 90 percent indicated that they would join another study

“The results from this survey inform tangible steps we can take as an industry to encourage more pediatric participation in clinical trials, including more decentralized clinical trial approaches, enhanced communication with caregivers about clinical trials as a care option and better engagement between industry and pediatric providers,” said Sy Pretorius, MD, Executive Vice President and Chief Medical & Scientific Officer at Parexel. “The pandemic has further demonstrated the benefits of bringing trials to patients in their homes, rather than asking patients to come into the clinic for every visit, and this is amplified in the context of pediatric trials.”

Pediatric participation in clinical trials is an issue of growing importance as the medical community has embraced the need to better understand the effects of medications in children. In 2012, Congress passed the Food and Drug Administration Safety and Innovation Act to incorporate pediatric evaluations earlier in the drug development process, legislation which has resulted in 500 pediatric-specific drug-labeling changes. 2

The Pediatric Perceptions & Insights Study was created, in part, as an outgrowth of questions included in the baseline CISCRP Perceptions & Insights Study that is conducted biennially in adult populations, which gauges public and patient perceptions, motivations, and experiences regarding clinical research participation. Its goal is to monitor trends and identify opportunities to better inform and engage the public and patients as stakeholders and partners in contributing to the clinical research enterprise.

To view the Pediatric Perceptions & Insights Study final report, visit https://www.ciscrp.org/wp-content/uploads/2020/09/Pediatric-PI-Survey-FINAL-2020.pdf

To hear a podcast about the survey results featuring a parent advocate survey respondent, please visit https://www.podbean.com/media/player/t2u24-f45cc0?from=pb6admin&download=1&version=1&auto=0&share=1&download=0&rtl=0&fonts=Helvetica&skin=1&pfauth=&btn-skin=107

About Parexel

Parexel is focused on supporting the development of innovative new therapies to improve patient health. We do this through a suite of services that help life science and biopharmaceutical customers across the globe transform scientific discoveries into new treatments for patients. From clinical trials to regulatory and consulting services to commercial and market access, our therapeutic, technical and functional ability is underpinned by a deep conviction in what we do. For more information, visit https://www.parexel.com/.

About CISCRP

CISCRP (Center for Information and Study on Clinical Research Participation) is an internationally recognized non-profit organization dedicated to educating and informing the public and patients about clinical research. Located in Boston, Massachusetts, CISCRP works to raise awareness, enhance experiences, and strengthen communication and relationships among participants, research professionals and the public through various services and events. For more information, visit https://www.ciscrp.org/.

References: 1https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345947/#:~:text=Despite%20about%2027%25%20of%20the,Organization%20(WHO)%20portal%2034

2 https://pediatrics.aappublications.org/content/144/4/e20191571

###

Share article on social media or email:

The Termeer Foundation Launches Henri Termeer Transatlantic Connections Award


The Termeer Foundation, a nonprofit organization focused on connecting life science innovators and catalyzing the creation of new medicines, today announced the creation of The Henri Termeer Transatlantic Connections Award.

The Award is part of an agreement signed in July 2019 between the Massachusetts Office of International Trade and Investment and the Dutch Ministry of Economic Affairs and Climate Policy, which created and signed a Memorandum of Understanding laying the basis for a Massachusetts – Netherlands Transatlantic Life Sciences Partnership. The signatories included Top Sector Life Sciences & Health (Health~Holland), MassBio, HollandBIO and the Henri A. Termeer Tribute Committee; all of whom agreed to provide support and organize activities to promote trans-Atlantic collaboration between the two biotechnology ecosystems.

“The establishment of the Henri Termeer Transatlantic Connections Award is the first of many partnerships this group plans to create that will help foster a strong relationship between life science communities in the Netherlands and Massachusetts,” said Belinda Termeer, President, Co-Founder and Member of the Board of Directors, The Termeer Foundation. “As a native of Holland, Henri was always interested in establishing working relationships with his homeland and his new business home in Cambridge. We are delighted at the creation of this award and feel that it will provide an excellent platform for identifying future industry ambassadors and the opportunity for collaborations between these two important life science sectors.”

The Henri Termeer Transatlantic Connections Award will be an annual award competition for life science entrepreneurs in the Netherlands and Massachusetts. Each year the Termeer Foundation and Health-Holland will select two young life science entrepreneurs, one in Massachusetts and one in the Netherlands, who are leading innovative biomedical research activities, and whose programs have the potential to strengthen transatlantic relations between the two life science regions. Candidates should have already established themselves within the life science industry leading an early-stage company, with a concrete business plan and initial funding in place. Additionally, the recipient will be someone interested in becoming actively involved in mentorship and who agrees to be involved in Termeer Foundation programs. Awardees receive Fellowship status within The Termeer Foundation, which includes access to experienced healthcare mentors, networking with fellow peer entrepreneurs, and recognition at The Termeer Foundation Annual Dinner. Recipients will also have the opportunity to spend a week visiting their fellow awardee’s company, and to participate in additional learning, networking and cultural events.

The winners of the 2021 Henri Termeer Transatlantic Connections Award will be announced at the end of April, 2021. Nominations should be submitted here.

“Life science research is increasingly developing into a global experience with partnerships between companies in diverse global locations becoming part of our industry’s DNA,” said Hans Schikan, board member of Health-Holland and a member of the Henri Termeer Transatlantic Connections Award Steering Committee. “One of the many important elements of the biotechnology business I learned from Henri Termeer during my time at Genzyme and as CEO of Prosensa, with Henri as an inspiring mentor, was the notion of understanding the needs of patients everywhere and applying our research in the development of treatments to address those needs no matter the location.”

Members of the Massachusetts – Netherlands Transatlantic Life Sciences Partnership Steering Committee include: Belinda Termeer (Co-Founder and Member of the Board of Directors, The Termeer Foundation), Alan Walts (Treasurer, Secretary, Mentor, Co-Founder and Member of the Board of Directors, The Termeer Foundation), Hans Schikan (Member Board of Directors, Health-Holland), Bob Coughlin (President/CEO, Massachusetts Biotechnology Council), Clémence Ross-van Dorp (Ambassador Life Sciences & Health Sector), Annemiek Verkamman (Managing Director, HollandBIO), John Maraganore (CEO and Director, Alnylam Pharmaceuticals), and Daniel de Boer (Founder and Chief Executive Officer, ProQR Therapeutics).

“I am delighted to support this award that will provide an incredible opportunity each year for two deserving life science entrepreneurs,” said Daniel de Boer, Founder and Chief Executive Officer of ProQR Therapeutics. “Reflecting on my personal experience, Henri’s influence has been invaluable and he was instrumental in helping me to navigate my entrance into the biotechnology industry as a CEO. We co-founded ProQR together, which is now based in the Netherlands and Massachusetts, embodying the spirit of this initiative and his legacy.”

About The Termeer Foundation

Building on the bold legacy of Henri Termeer, who pioneered groundbreaking treatments for rare diseases, The Termeer Foundation connects life science innovators and catalyzes the creation of new medicines. The Foundation’s network of emerging and established healthcare innovators cultivates tomorrow’s leaders and leverages their collective expertise to solve complex problems in drug development and accessibility. The Foundation also integrates its network with academic institutions, nonprofits, regulatory agencies and other organizations across the global healthcare ecosystem to provide expert counsel, stimulate innovation, eliminate barriers to progress, and ultimately connect the world of healthcare until every patient has a cure. Visit us at http://www.termeerfoundation.org or on LinkedIn @TermeerFoundation.

Contact:

Paul Kidwell

Termeer Foundation

617-680-1088

paulkidwell@comcast.net

Share article on social media or email:

Planet 13 Teams Up to Give Back in a Big Way this Holiday Season


News Image

This has been a very tough year for many families, so it only makes sense for us to do what we can to help. Our mission is to make the holidays brighter for as many local families as possible.

Planet 13, a leading vertically-integrated Nevada cannabis company is famous for doing everything bigger and that also applies to spreading hope and joy.

Known for its award-winning brands, cultivation, production and dispensary operations, Planet 13 is proud to celebrate the holidays by giving back to the community. On Dec. 7, Planet 13 donated 25,000 Cans of food and toys to the Las Vegas Rescue Mission and SafeNest.

Two semi-trailer trucks loaded the donations at the SuperStore at 2548 W Desert Inn Rd, Las Vegas. Customers, vendors, and staff contributed to this colossal donation.

Along with Planet 13 and Green Life Productions (GLP), sponsored vendors including TRENDI, ROVE, Dreamland Chocolates, Cannabella, Evergreen Organix, MOXIE, OMG THC, MEDIZIN, Nature’s Chemistry, HaHa, and LEAF & VINE gave generously.

“This has been a very tough year for many families, so it only makes sense for us to do what we can to help,” said David Farris Planet 13 V.P. of Sales and Marketing. “We are incredibly appreciative of everyone who donated to our holiday canned food and toy drive along with the GLP team and sponsored vendors. Our mission is to make the holidays brighter for as many local families as possible.”

The Las Vegas Rescue Mission campus takes up two city blocks in downtown Las Vegas, helping hundreds of men, women and their children daily, and providing approximately 30,000 meals each month. SafeNest is Nevada’s largest, most comprehensive nonprofit dedicated to ending domestic violence.

The donations will continue to come-in at Planet 13 until Dec.15, 2020.

About Planet 13

Planet 13 (http://www.planet13holdings.com) is a vertically integrated cannabis company based in Nevada, with award-winning cultivation, production and dispensary operations in Las Vegas – the entertainment capital of the world. Planet 13’s mission is to build a recognizable global brand known for world-class dispensary operations and a creator of innovative cannabis products. Planet 13’s common shares trade on the Canadian Securities Exchange (CSE) under the symbol PLTH and on the OTCQX under the symbol PLNHF.

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking-statements relate to, among other things, future expansion plans.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: final regulatory and other approvals or consents; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Nevada cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in the State of Nevada; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational and medicinal cannabis marketplace in the United States through its subsidiary MMDC. Local state laws where MMDC operates permit such activities however, these activities are currently illegal under United States federal law. Additional information regarding this and other risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form dated April 30, 2019 filed on its issuer profile on SEDAR at Sedar.com.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Share article on social media or email:

For Human Rights Day, United Nations Office on Drug & Crime Partners with NFL Superbowl Champion Dr. Koonce and Touchdown for Humanity to Aid Parents during COVID-19


Dr George Koonce

“This program is exactly what children and their parents around the world need right now. Factual, caregiving tips based on science but presented in an enjoyable, realistic and loving way.” Dr George Koonce

On Human Rights Day we commemorate the Universal Declaration of Human Rights. This year’s theme is the global COVID-19 pandemic and its aftermath; children worldwide are suffering ever more due to COVID-19. Millions are unable to attend schools, especially girls in developing countries, and many lack access to food, shelter, and healthcare as parents are also under extreme pressure. To that end, United Nations Office on Drug & Crime (UNODC) is launching “Listen First: The Science of Care,” ten videos and written campaign of information produced by Ethan Films for parents worldwide to help their children and better prepare them for the future, based on scientific evidence worldwide. Each episode focuses on a parenting tip, offering the scientific reasons why it helps.

For example, one video demonstrates how affection, such as a hug, generates oxytocin, a chemical in the brain, which can stimulate growth, strengthen the immune system and make children grow smarter, healthier, and happier. Equally as important is “patient parenting,” because patience makes children feel cared for and loved, plus neuroscience shows that the child’s brain is not mature enough to calmly handle frustration. In the current video, the parents’ patience leads the children to be successful in their efforts to score a winning touchdown. The campaign is spread online using the hashtags #scienceofcare and #listenfirst, and is highlighted across various organizations including the Walther Center in Global Palliative Care & Supportive Care at Indiana University, Olympic Coach and Athlete networks, on Dr. Koonce’s TV show and more. Dr. Koonce, formerly star linebacker for the Superbowl-winning Green Bay Packers and on their Board of Directors, grew up in poverty himself, and is now Senior Vice President for University Relations at Marian University.

“Parents more than ever need proven strategies, based on science,” says Giovanna Campello, Chief UNODC Prevention, Treatment & Rehabilitation Section, “to support how they raise their children. As people are forced to work from home, and as Covid-19 contributes to increased stress, more than ever we need to focus on the needs of the children. The buy-in already from governments around the world is extraordinary, ranging from Indonesia to Slovenia, Russia, and France.”

The materials, including scientific resources, are all available at:

http://www.unodc.org/listenfirst

The new video on Patience can be seen here:

https://www.unodc.org/unodc/en/listen-first/success-stories/touch-down-for-humanity

It can be downloaded here:

https://vimeo.com/483473315

Social Media

Twitter

UNODC_PTRS

Facebook

@UNODCYouthInitiative

@EthanFilms

For interviews with UNODC or the Touchdown for Humanity Team, please contact: miles@ethanfilms.com Phone:+34 632 739 699

Share article on social media or email:

Tune in To CNBC on Saturday, 12/12 @2:30p ET to watch New Episode of Advancements


News Image

The award-winning series, Advancements with Ted Danson, will broadcast on Saturday, December 12, 2020 @2:30p ET via CNBC. Check local listings for more information.

In this episode, Jupiter, FL— Advancements will educate about Nanoform’s multi-patented award-winning CESS® technology, which has the potential to double the number of lead compounds progressing into clinic. Audiences will hear how the advanced production of nanoparticles provides pharmacokinetic improvements, commercial opportunities, and novel avenues for drug delivery.

Viewers will learn how MissingLogic is revolutionizing the healthcare industry by helping executives in healthcare systems see their most significant challenges through a polarity lens. Leveraging its H20 FrameworkSM to help healthcare leaders navigate the complexity and uncertainties in healthcare today, the show will explore how MissingLogic enables executives to break through complexity and the never-ending cycle of re-occurring issues, while navigating their organizations through COVID-19 and beyond.

Hearing from doctors in the field, spectators will see how ChenMed is reinventing preventative, VIP care for seniors. With 24-7-access to doctors, on-site medications, and transportation to appointments, the show will explore how ChenMed’s replicable, successful model puts primary care physicians in charge of outcomes and the patient experience.

Advancements will also showcase the intellectual and technical expertise behind Complete Phytochemical Solutions, LLC, a phytochemistry company dedicated to developing, manufacturing, and marketing high quality and efficacious botanical and food products for human and animal nutrition.

“This episode will take a look at how COVID has been affecting the healthcare sector and beyond, as we explore impact it’s had on drug development, burnout, telehealth, and quality standards,” said Creative Director, Sarah McBrayer.

###

About Advancements and DMG Productions:

The Advancements television series is an information-based educational program, targeting recent advances across a number of industries and economies. Featuring state-of-the-art solutions and important issues facing today’s consumers and business professionals, Advancements focuses on cutting-edge developments, and brings this information to the public with the vision to enlighten about how technology and innovation continue to transform our world.

Backed by experts in various fields, and a team dedicated to education and advancement, DMG Productions consistently produces commercial-free, educational programming on which both viewers and networks depend.

For more information visit Jupiter, FL— http://www.AdvancementsTV.com or call (866) 496-4065.

Share article on social media or email:

DrOwl Celebrates Over 1M COVID-19 Check-Ins On Its Award-Winning Free Mobile App


To date, we have seen that schools really appreciate that we provide an automatically-generated list of check-in questions that they can customize as needed. It enables them to save precious time while helping create a new, safer normal for their community.

DrOwl, an award-winning medical platform built on patented technology that helps users better understand their medical history– has surpassed one million electronic screenings by its users. DrOwl includes a free COVID-19 screening tool for people to screen for symptoms and history of exposure to COVID-19, following the CDC guidelines. DrOwl’s groundbreaking user-friendly app assists organizations around the country, by eliminating ineffective and time-consuming paper-based questionnaires, while enabling users to easily check-in to businesses, schools, or their favorite restaurants on their smartphone. DrOwl also provides the businesses and schools with a way to give reports to public health departments of visitors to their facilities in just a few clicks.

DrOwl is honored to have reached this landmark number of electronic screenings. We know our check-in/screening feature furthers our work as a medical platform that enables the average person to securely access, understand, and share his/her personal medical information. With uncertainty looming as the pandemic rages on, this key check-in feature will continue to help serve as a lifeline for organizations throughout the pandemic — while hopefully helping to prevent any additional spread of COVID-19.

“The millionth check-in is an extremely humbling milestone; it demonstrates the power of not only DrOwl’s unique tool but also the willingness of communities working together to help mitigate the spread of COVID-19”, said Arvind Raichur, CEO, and Co-Founder of DrOwl.

“We’ve been working hand in hand, tirelessly with community leaders, lawmakers, educators, and small businesses across the country. What we have seen consistently is that business owners and leaders want to keep their employees and visitors safe by following the CDC guidelines”, he said.

“We know that there is still much to do, but we are confident that by being more proactive, communities across the nation can help return to their new normal more safely. This, in and of itself, is comforting. To know we are making a difference by enabling people to keep each other safe. At DrOwl, this is how we’re doing our part”.

The Millionth Check-In

The millionth check-in was completed on November 17, 2020, and shows the ease of use that organizations around the nation are flocking towards. Since screening has become a primary tool for COVID tracking, electronic check-ins are the most efficient tool we have to manage that data.

DrOwl’s mobile app enables facilities to have their guests, employees, and visitors check-in, while on the go. Visitors arrive at a given location, electronically check-in, and are automatically shown the organization’s customizable screening questions on their smartphone. This makes organizing and maintaining the data more convenient for facilities while simplifying the check-in process for visitors. Restaurant patrons can check-in without hassle, the same way senior living facilities can, and facilities can easily download visitor reports with the click of a button to give to public health departments. And organizations can even generate a custom QR code for their location.

“To date, we have seen that schools really appreciate that we provide an automatically-generated list of check-in questions that they can customize as needed. It enables them to save precious time while helping create a new, safer normal for their community. When organizations such as rehabilitation facilities or senior living communities have specific rules and challenges, customization has become their best friend and ally,” said Raichur.

With over one million check-ins completed to date, DrOwl is on the cutting edge on the transformation of how businesses and organizations adapt to our current – and future challenges. With a central database enabling administrators to run on-demand reports, and cross-reference those that have entered a given facility in real-time. Making it easy for organizations to use the data for epidemiological usage and in cases of infection, look at the data to help assess the risks to help limit their potential liabilities. For more information on DrOwl, please visit CheckIn.DrOwl.com. And, users can download DrOwl.com for free from the iTunes or Google Play app stores.

About DrOwl

DrOwl is a medical platform built on patented technology, that provides a safe place to sync, organize, search, and share your digital medical records on-demand.

Once a user securely syncs their medical records, DrOwl uses AI and machine learning to provide users with a Patient Portal based on the Patient’s health records that include trusted, doctor-approved sources of information that is customized for each user and makes their medical information easier to understand. DrOwl users can also share their customized Patient Portal with caregivers or family members to include them in the patient’s healthcare decisions. Users can also initiate telehealth sessions 24×7 and allow their caregivers or family members to join in the secure telemedicine video call.*

DrOwl also has a free electronic screening and monitoring solution to help protect schools, senior communities, and businesses during infectious disease outbreaks. Where staff, residents, and visitors can electronically “check-in”, answering a list of questions that helps screen for symptoms and history of exposure. This creates an electronic log of employee and visitor activity, in real-time. And reports can be run as needed to assist in contact tracing if an infection is reported. In cases of infection, there is electronic tracking with centralized data for epidemiological usage and cross-contamination data to help assess the risks.

*Telemedicine available in select areas with more being added all the time.

Share article on social media or email:

Relapsing Polychondritis Patients and Advocates Emphasize the Benefits of Collaboration in Prestigious Patient Perspective Poster Program


News Image

We were honored to have so many RP patients represented and encouraged by the progress of the research, which was presented to 16,000 attendees.

The American College of Rheumatology (ACR) held its annual meeting, ACR Convergence 2020, on November 5-9th. The all-virtual meeting included clinical and basic science symposia, notable speakers such as Dr. Anthony S. Fauci, Director of the National Institute of Allergy and Infectious Diseases, a virtual exhibit hall, and patient perspective posters and presentations authored by individuals with rheumatic disease.

This year’s annual meeting also featured five relapsing polychondritis patient poster submissions that were selected for presentation. Four of the posters were sponsored by the Relapsing Polychondritis Foundation and one poster was sponsored by the Canadian Society for Relapsing Polychondritis.

“Poster presentations like these are an important part of our efforts,” said David Bammert, President of the RP Foundation. “They provide the opportunity for the medical community to better understand the patient’s perspective regarding living with RP and facilitate pathways for more efficient patient care.”

Nancy Linn presented her poster, Connecting Rheumatology Professionals & Thought Leaders Inspired the Creation of a New Program Focused on Relapsing Polychondritis, a Rare Rheumatic Disease, outlining the ideation and establishment of the Penn RP Fund, a research initiative and partnership between the University of Pennsylvania RP Program and the National Institutes of Health (NIH) sponsored Vasculitis Clinical Research Consortium (VCRC) made possible by relationships fostered at previous ACR meetings and other similar gatherings of clinicians, researchers, patients, and advocates.

Isabel Bautista’s poster, Patients With Relapsing Polychondritis and an Advocate Manufactured Custom Cloth Masks to Combat COVID-19: This Mask Project Provided a Sense of Purpose, Created Unity, Increased Awareness of RP, Facilitated Research, and Generated Hope, detailed the story of her team of RP patients who helped patients across the globe by making and distributing free masks and ear savers to protect them from COVID-19 during the pandemic. Ms. Bautisa was one of only four patients selected to present her poster to ACR attendees.

With Coping Through Advocacy – My Story Living With Relapsing Polychondritis, Allegonda Imeson shared her story about founding the Canadian Society for Relapsing Polychondritis as a means of spreading awareness about the disease and supporting patients, including herself.

Tedi LaMere’s presentation of My Multidisciplinary Healthcare Team and Patient Advocacy Groups Saved My Life followed her RP story from onset to diagnosis and treatment and revealed how through the help of Friends of Patients, NIH specialists were able to identify and address several life-threatening conditions she faced.

Dan Smith’s poster, Only in My Dreams Can I Do the Things I Used To Do: Where There is Research There is Hope, illustrated the positive impacts of finding a support group and new creative pursuits to promote well-being.

While each poster highlights different aspects of patient engagement, intervention, and self-management of this rare disease, an overarching theme of collaboration and partnership emerged. As they worked hard to find purpose and find ways to cope with their illness, the patient-presenters sought out community and support and became relapsing polychondritis and autoimmune disease advocates actively engaged in helping other patients, promoting increased awareness, and pushing for greater research – each in their own way – resulting in improved quality of life for many.

“We were honored to have so many RP patients represented and encouraged by the progress of the research, which was presented to 16,000 attendees. ACR did an outstanding job facilitating this exciting and informative forum,” said David DeRosa, Secretary / Treasurer of the RP Foundation.

Additional information regarding ACR Convergence 2020 Patient Perspective Poster Educational Sessions and Oral Abstracts can be found here.

About Relapsing Polychondritis

Relapsing polychondritis (RP) is a debilitating and sometimes fatal systemic inflammatory disease that is characterized by recurrent inflammation of cartilage and other tissues throughout the body. The disease affects multiple organs, particularly cartilaginous structures such as the ears, nose, airways and joints as well as eyes, skin, heart valves and brain. The cause of RP is unknown and there is no cure for RP. For more information, visit https://bit.ly/RP_Poster.

About Relapsing Polychondritis Foundation

The RP Foundation’s purpose is to facilitate education, awareness and research initiatives that improve the quality of life for patients with RP. For more information, visit https://www.polychondritis.org.

About Race for RP

Race for RP supports research and awareness programs for relapsing polychondritis and related diseases. For more information, visit http://www.RaceforRP.org or http://www.facebook.com/raceforrp. Follow Race for RP on Instagram and Twitter, @RaceforRP.

Share article on social media or email: